Star Equity Holdings, Inc. (STRR)
USD 2.36
(-2.88%)
USD 2.36
(-2.88%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 16.27 Million USD | -49.84% |
| 2022 | 28.98 Million USD | 19.16% |
| 2021 | 24.32 Million USD | 17.17% |
| 2020 | 20.75 Million USD | -11.17% |
| 2019 | 23.36 Million USD | 7.04% |
| 2018 | 21.83 Million USD | -31.07% |
| 2017 | 31.67 Million USD | -2.09% |
| 2016 | 32.35 Million USD | 113.74% |
| 2015 | 15.13 Million USD | 12.7% |
| 2014 | 13.43 Million USD | -2.58% |
| 2013 | 13.78 Million USD | -24.22% |
| 2012 | 18.19 Million USD | -1.31% |
| 2011 | 18.43 Million USD | 1.06% |
| 2010 | 18.23 Million USD | -8.11% |
| 2009 | 19.84 Million USD | -24.78% |
| 2008 | 26.38 Million USD | 12.96% |
| 2007 | 23.35 Million USD | -14.38% |
| 2006 | 27.28 Million USD | 3.94% |
| 2005 | 26.24 Million USD | 23.95% |
| 2004 | 21.17 Million USD | 25.66% |
| 2003 | 16.85 Million USD | -23.48% |
| 2002 | 22.02 Million USD | 450.6% |
| 2001 | 3.99 Million USD | -56.88% |
| 2000 | 9.27 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 4.09 Million USD | 27.5% |
| 2024 Q2 | 5.33 Million USD | 30.41% |
| 2023 Q4 | 3.21 Million USD | -16.9% |
| 2023 Q3 | 3.86 Million USD | -16.71% |
| 2023 FY | 14.53 Million USD | -49.84% |
| 2023 Q1 | 6.86 Million USD | -4.4% |
| 2023 Q2 | 4.63 Million USD | -32.41% |
| 2022 FY | 28.98 Million USD | 19.16% |
| 2022 Q1 | 7.21 Million USD | 0.45% |
| 2022 Q2 | 3.62 Million USD | -49.78% |
| 2022 Q3 | 7.29 Million USD | 101.1% |
| 2022 Q4 | 7.17 Million USD | -1.52% |
| 2021 Q3 | 5.63 Million USD | -6.37% |
| 2021 Q2 | 6.01 Million USD | 9.48% |
| 2021 FY | 24.32 Million USD | 17.17% |
| 2021 Q1 | 5.49 Million USD | -8.48% |
| 2021 Q4 | 7.18 Million USD | 27.61% |
| 2020 FY | 20.75 Million USD | -11.17% |
| 2020 Q2 | 5.55 Million USD | -21.19% |
| 2020 Q3 | 6.36 Million USD | 14.7% |
| 2020 Q4 | 6 Million USD | -5.75% |
| 2020 Q1 | 7.04 Million USD | -9.17% |
| 2019 FY | 23.36 Million USD | 7.04% |
| 2019 Q4 | 7.75 Million USD | 45.05% |
| 2019 Q1 | 5.11 Million USD | -0.41% |
| 2019 Q2 | 5.15 Million USD | 0.66% |
| 2019 Q3 | 5.34 Million USD | 3.83% |
| 2018 Q4 | 5.13 Million USD | -0.08% |
| 2018 Q3 | 5.14 Million USD | -3.71% |
| 2018 FY | 21.83 Million USD | -31.07% |
| 2018 Q1 | 6.21 Million USD | -25.65% |
| 2018 Q2 | 5.33 Million USD | -14.11% |
| 2017 Q1 | 8.08 Million USD | 18.38% |
| 2017 FY | 31.67 Million USD | -2.09% |
| 2017 Q4 | 8.36 Million USD | 29.67% |
| 2017 Q3 | 6.44 Million USD | -26.59% |
| 2017 Q2 | 8.78 Million USD | 8.69% |
| 2016 Q1 | 9.61 Million USD | 129.33% |
| 2016 Q4 | 6.82 Million USD | -10.31% |
| 2016 Q3 | 7.61 Million USD | -8.21% |
| 2016 FY | 32.35 Million USD | 113.74% |
| 2016 Q2 | 8.29 Million USD | -13.78% |
| 2015 Q2 | 3.6 Million USD | 3.47% |
| 2015 FY | 15.13 Million USD | 12.7% |
| 2015 Q4 | 4.19 Million USD | 8.82% |
| 2015 Q1 | 3.48 Million USD | 1.4% |
| 2015 Q3 | 3.85 Million USD | 6.94% |
| 2014 Q1 | 3.15 Million USD | 9.85% |
| 2014 Q2 | 3.54 Million USD | 12.23% |
| 2014 FY | 13.43 Million USD | -2.58% |
| 2014 Q4 | 3.43 Million USD | 4.19% |
| 2014 Q3 | 3.29 Million USD | -6.92% |
| 2013 Q2 | 3.81 Million USD | -9.64% |
| 2013 FY | 13.78 Million USD | -24.22% |
| 2013 Q4 | 2.87 Million USD | -0.07% |
| 2013 Q3 | 2.87 Million USD | -24.64% |
| 2013 Q1 | 4.22 Million USD | -5.19% |
| 2012 FY | 18.19 Million USD | -1.31% |
| 2012 Q3 | 4.19 Million USD | -8.52% |
| 2012 Q2 | 4.58 Million USD | -7.41% |
| 2012 Q1 | 4.95 Million USD | -11.87% |
| 2012 Q4 | 4.45 Million USD | 6.12% |
| 2011 Q1 | 4.16 Million USD | -1.79% |
| 2011 FY | 18.43 Million USD | 1.06% |
| 2011 Q4 | 5.62 Million USD | 33.77% |
| 2011 Q3 | 4.2 Million USD | -1.82% |
| 2011 Q2 | 4.28 Million USD | 2.74% |
| 2010 FY | 18.23 Million USD | -8.11% |
| 2010 Q1 | 4.74 Million USD | 0.94% |
| 2010 Q4 | 4.24 Million USD | -7.44% |
| 2010 Q3 | 4.58 Million USD | -1.8% |
| 2010 Q2 | 4.66 Million USD | -1.73% |
| 2009 FY | 19.84 Million USD | -24.78% |
| 2009 Q2 | 5.25 Million USD | 3.78% |
| 2009 Q3 | 4.83 Million USD | -7.92% |
| 2009 Q1 | 5.05 Million USD | -40.49% |
| 2009 Q4 | 4.7 Million USD | -2.67% |
| 2008 Q1 | 6.11 Million USD | 5.29% |
| 2008 Q2 | 5.96 Million USD | -2.34% |
| 2008 Q3 | 5.8 Million USD | -2.76% |
| 2008 Q4 | 8.5 Million USD | 46.47% |
| 2008 FY | 26.38 Million USD | 12.96% |
| 2007 Q4 | 5.8 Million USD | 1.03% |
| 2007 Q1 | 5.85 Million USD | 6.26% |
| 2007 Q2 | 5.95 Million USD | 1.57% |
| 2007 FY | 23.35 Million USD | -14.38% |
| 2007 Q3 | 5.74 Million USD | -3.43% |
| 2006 Q2 | 7.3 Million USD | -5.0% |
| 2006 Q3 | 6.76 Million USD | -7.38% |
| 2006 FY | 27.28 Million USD | 3.94% |
| 2006 Q1 | 7.69 Million USD | 18.46% |
| 2006 Q4 | 5.51 Million USD | -18.56% |
| 2005 Q3 | 6.62 Million USD | -1.97% |
| 2005 Q4 | 6.49 Million USD | -1.9% |
| 2005 FY | 26.24 Million USD | 23.95% |
| 2005 Q1 | 6.38 Million USD | 12.62% |
| 2005 Q2 | 6.75 Million USD | 5.81% |
| 2004 Q4 | 5.66 Million USD | 4.3% |
| 2004 Q2 | 5.3 Million USD | 11.29% |
| 2004 FY | 21.17 Million USD | 25.66% |
| 2004 Q3 | 5.43 Million USD | 2.35% |
| 2004 Q1 | 4.76 Million USD | 0.0% |
| 2003 Q2 | 595.72 Thousand USD | -14.72% |
| 2003 Q1 | 698.52 Thousand USD | 0.0% |
| 2003 FY | 16.85 Million USD | -23.48% |
| 2002 FY | 22.02 Million USD | 450.6% |
| 2001 FY | 3.99 Million USD | -56.88% |
| 2000 FY | 9.27 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | 89.079% |
| Prenetics Global Limited | 60.73 Million USD | 73.209% |
| CareDx, Inc | 277.76 Million USD | 94.142% |
| Exact Sciences Corporation | 2.06 Billion USD | 99.21% |
| Exagen Inc. | 52.29 Million USD | 68.883% |
| Inotiv, Inc. | 246.9 Million USD | 93.41% |
| Guardant Health, Inc. | 901.62 Million USD | 98.195% |
| Biodesix, Inc. | 77.41 Million USD | 78.982% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -314.776% |
| Precipio, Inc. | 13.63 Million USD | -19.314% |
| iSpecimen Inc. | 16.27 Million USD | 0.032% |
| Natera, Inc. | 938.98 Million USD | 98.267% |
| Aspira Women's Health Inc. | 24.11 Million USD | 32.521% |
| Standard BioTools Inc. | 113.48 Million USD | 85.662% |
| 23andMe Holding Co. | 420.73 Million USD | 96.132% |
| Castle Biosciences, Inc. | 242.78 Million USD | 93.298% |
| Personalis, Inc. | 128.14 Million USD | 87.302% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | 85.278% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | 1.302% |
| OpGen, Inc. | 30.65 Million USD | 46.924% |
| T2 Biosystems, Inc. | 41.49 Million USD | 60.785% |
| Myriad Genetics, Inc. | 600.1 Million USD | 97.288% |
| ICON Public Limited Company | 755.64 Million USD | 97.847% |
| NeoGenomics, Inc. | 341.25 Million USD | 95.232% |
| Star Equity Holdings, Inc. | 16.27 Million USD | 0.0% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 98.511% |
| RadNet, Inc. | 268.87 Million USD | 93.948% |
| MDxHealth SA | 71.25 Million USD | 77.164% |
| Psychemedics Corporation | 11.33 Million USD | -43.568% |
| Illumina, Inc. | 3.81 Billion USD | 99.573% |
| Check-Cap Ltd. | 19.28 Million USD | 15.632% |
| Twist Bioscience Corporation | 354.18 Million USD | 95.406% |
| DarioHealth Corp. | 62.17 Million USD | 73.828% |
| Fulgent Genetics, Inc. | 171.9 Million USD | 90.534% |
| Sera Prognostics, Inc. | 39.91 Million USD | 59.235% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -54.666% |
| OPKO Health, Inc. | 574.68 Million USD | 97.169% |
| Medpace Holdings, Inc. | 187.68 Million USD | 91.33% |
| Neogen Corporation | 405.23 Million USD | 95.985% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -38.972% |
| Prenetics Global Limited | 60.73 Million USD | 73.209% |
| Mainz Biomed B.V. | 27.15 Million USD | 40.076% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -85.651% |
| Trinity Biotech plc | 46.49 Million USD | 65.003% |
| Neuronetics, Inc. | 82.25 Million USD | 80.219% |
| Sotera Health Company | 300.46 Million USD | 94.584% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -85.651% |